BVT Aktienanleihe MRK 28.06.2024/ DE000VU6YF08 /
2024-05-10 10:32:50 AM | Chg.-0.140 | Bid1:23:17 PM | Ask1:23:17 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
94.790EUR | -0.15% | 94.660 Bid Size: 500,000 |
94.760 Ask Size: 500,000 |
MERCK KGAA O.N. | 165.00 EUR | 2024-06-28 | Call |
GlobeNewswire
05-09
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurre...
GlobeNewswire
05-09
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA